Antimicrobial resistance (AMR) is one of the greatest challenges for global health and development. According to estimates by the World Health Organisation (WHO), almost five million deaths worldwide
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)
Microorganisms produce a wide variety of natural products that can be used as active agents to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the
On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of
The development of an effective vaccine against the hepatitis C virus has been an enormous challenge for decades due to the high genetic diversity of the virus. The research team led by DZIF scientist
Two DZIF junior scientists—Prof Philipp Schommers and Dr Alexander Simonis—have been honoured with silver medals by the Walter Siegenthaler Society for their fundamental medical research in the field
Eleven scientists from the German Center for Infection Research (DZIF) are among the “Highly Cited Researchers 2024”. The ranking, published on 19 November by the company Clarivate Analytics, lists
Prof. Tanja Schneider, Head of the Institute of Pharmaceutical Microbiology at the University Hospital Bonn (UKB) and Deputy Coordinator of the “New Antibiotics” research area at the German Center for
Antibacterial drugs are important for treating infections. However, increasing bacterial resistance to current drugs—making them ineffective or only partially effective—means that new drugs are
DZIF scientist Michael Ramharter from the Bernhard Nocht Institute for Tropical Medicine in Hamburg and the University Medical Center Hamburg-Eppendorf has received the Memento Research Prize 2024
